Evidence map›Paper›PMID 29851662›Full record

ArticleAIDS (London, England)2018

Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status.

Rachel M Presti, Scott A Handley, Lindsay Droit, Mahmoud Ghannoum, Mark Jacobson, Caroline H Shiboski, Jennifer Webster-Cyriaque, Todd Brown, Michael T Yin, Edgar T Overton

Open access · bronzeAbstract read
In one paragraph

Article in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. A Review of the Impact of Green Tea (Current pharmaceutical design · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Rachel M PrestiWashington University School of Medicine, St. Louis, Missouri.
Scott A HandleyWashington University School of Medicine, St. Louis, Missouri.
Lindsay DroitWashington University School of Medicine, St. Louis, Missouri.
Mahmoud GhannoumCase Western Reserve, Cleveland, Ohio.
Mark JacobsonUniversity of California, San Francisco, San Francisco, California.
Caroline H ShiboskiUniversity of California, San Francisco, San Francisco, California.
Jennifer Webster-CyriaqueUniversity of North Carolina, Chapel Hill, North Carolina.
Todd BrownJohn Hopkins University, Baltimore, Maryland.
Michael T YinColumbia University Medical Center, New York, New York.
Edgar T OvertonUniversity of Alabama, Birmingham, Alabama, USA.
Washington University in St. Louis · USUniversity of California, San Francisco · USCase Western Reserve University · USColumbia University Irving Medical Center · USJohns Hopkins University · USUniversity of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Vanderbilt HIV Clinical Trials Unit (CTU)UM1AI069439 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David W Haas, Spyros A Kalams · 2012 to 2026
$33.1M
Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
NCATS NIH HHS UL1 TR000170NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069470NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI106716NIAID NIH HHS UM1 AI68636
6 · The paper itself

Abstract

objectiveTo characterize the oral bacterial microbiome in HIV-infected participants at baseline and after 24 weeks of EFV/FTC/TDF.

designThirty-five participants co-enrolled in two AIDS Clinical Trials Group (ACTG) studies, A5272 and A5280, with paired saliva samples and complete data sets were assessed.

methodsPaired saliva samples were evaluated for bacterial microbiome using 16S rDNA PCR followed by Illumina sequencing. Diversity and differential abundance was compared between groups. A random forest classification scheme was used to determine the contribution of parameters in classifying participants' CD4+ T-cell count.

resultsBacterial communities demonstrated considerable variability both within participants and between timepoints, although they became more similar after 24 weeks of ART. At baseline, both the number of taxa detected and the average alpha diversity were variable between participants, but did not differ significantly based on CD4+ cell count, viral load or other factors. After 24 weeks of ART samples obtained from participants with persistently low CD4+ T-cell counts had significantly higher bacterial richness and diversity. Several differentially abundant taxa, including Porphyromonas species associated with periodontal disease, were identified, which discriminated between baseline and posttreatment samples. Analysis demonstrated that although inflammatory markers are important in untreated disease, the salivary microbiome may play an important role in CD4+ T-cell count recovery after ART.

conclusionShifts in the oral microbiome after ART initiation are complex, and may play an important role in immune function and inflammatory disease.

Indexed as

MicrobiotaAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCluster AnalysisCohort StudiesDNA, BacterialDNA, RibosomalFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedPhylogenyAnti-Retroviral AgentsDNA, BacterialDNA, RibosomalRNA, Ribosomal, 16S

Identifiers

PMID29851662
PMCPMC6198320
OpenAlexW2807708778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.